ProCE Banner Activity

KEYNOTE-061: Phase III Trial of Second-line Pembrolizumab vs Paclitaxel in Previously Treated, Unresectable Gastric or Gastroesophageal Junction Cancer

Slideset Download
Conference Coverage
Final analysis of phase III trial showed no significant improvement with pembrolizumab vs paclitaxel in OS, PFS, or response in patients with previously treated gastric/GEJ cancer and PD-L1 CPS ≥ 1.

Released: June 12, 2018

Expiration: June 11, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Astellas Text

AstraZeneca

Celgene

Eisai

Genentech TEXT Only

Janssen

Merck Oncology

Seagen